Brief: Hyphens Pharma International To Develop, Commercialise Byfavo Procedural Sedation Drug In Singapore
17/05/2023 11:38
May 17 (Reuters) - Hyphens Pharma International Ltd
HYPH.SI :
* TO DEVELOP AND COMMERCIALISE BYFAVO PROCEDURAL SEDATION
DRUG IN
SINGAPORE
* UNIT SIGNED EXCLUSIVE SUB-LICENSE AND SUPPLY AGREEMENT
WITH HANA
PHARM CO.
Source text for Eikon: ID:nSN2X1H5w
Further company coverage: HYPH.SI
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyphens Pharma International
See all newsBrief: Hyphens Pharma International Updates On Cerapro® Med Skin Barrier Cream
Brief: Hyphens Pharma International Says Unit Gets Exclusive Rights To Commercialise Metoject
Brief: Hyphens Pharma International Posts FY Net Income Of SGD 10.9 Million
Brief: Hyphens Pharma International Licenses Amenalief From Maruho For ASEAN
Brief: Hyphens Pharma International Posts Net Profit After Tax In 1Q2024 S$2.7 Million